Drug Trial Radar · NCT05184088
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
Jan 13, 2023
Primary completion
Apr 21, 2026
Study completion May 5, 2026
Sponsor
- Lead sponsor
- Lantheus Germany GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- pharmtrace klinische Entwicklung GmbH
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
Conditions
- Cardiac Amyloidosis
- AL Amyloidosis
- ATTR Amyloidosis
Interventions
[18F]florbetabenDrug
All enrolled patients will undergo \[18F\]florbetaben PET imaging.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis.Time frame: Up to 12 weeks
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
St Luke's Hospital
Kansas City, Kansas
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
University of Augsburg
Augsburg, Germany
Charite Berlin
Berlin, Germany
University of Essen
Essen, Germany
HOPA Hamburg
Hamburg, Germany
University of Heidelberg
Heidelberg, Germany
University of Würzburg
Würzburg, Germany
Hospital University Bellvitge
Barcelona, Spain
Hospital University Puerta de Hierro
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Spain
University of Salamanca
Salamanca, Spain
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.